3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
157
Lung Neoplasms
73
Small Cell Lung Carcinoma
52
Neoplasms
8
Melanoma
8
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Mesothelioma, Malignant
6
Mesothelioma
6
Colorectal Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Respiratory Tract Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Diseases
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Bronchogenic
3
Bronchial Neoplasms
3
Adenocarcinoma of Lung
3
Interventions
osimertinib
1
durvalumab
1
anlotinib
1
aflutinib
1
Radiosurgery
1
Monatide (IMS 3015)
1
Immunotherapy
1
Docetaxel
1
Circulating Tumor DNA
1
Chemotherapy, Adjuvant
1
Biological Assay
1
Adjuvants, Pharmaceutic
1
AST5902
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
durvalumab
×
Thoracic
×
Clear all
NCT04944173
2024-09-03
SCION
University of British Columbia
Phase 2
Withdrawn